Literature DB >> 10629810

The natural food grade inhibitor, lacticin 3147, reduced the incidence of mastitis after experimental challenge with Streptococcus dysgalactiae in nonlactating dairy cows.

M P Ryan1, J Flynn, C Hill, R P Ross, W J Meaney.   

Abstract

Lacticin 3147 is a broad-spectrum bacteriocin produced by the food-grade organism Lactococcus lactis. Lacticin 3147 is active at a neutral pH and has been shown to be bactericidal to streptococci and staphylococci in vitro. The effectiveness of an intramammary teat seal formulation, and a teat seal containing lacticin 3147 was evaluated at drying off in 68 uninfected quarters of 18 cows. Following infusion of either teat seal or lacticin 3147 combined with teat seal, a deliberate infection challenge of Streptococcus dysgalactiae (approximately equal to 1.5 x 10(4) cfu per teat) was administered by direct inoculation into the teat sinus. During an 8-d experimental period following inoculation, 61% of control quarters and 6% of the treatment quarters either developed clinical mastitis or were shedding the challenge organism. Randomly amplified polymorphic DNA polymerase chain reaction genetic typing was used to confirm that both the new infections and the bacteria surviving in the teats at the end of the experiment were the challenge strain. The combination of teat seal and lacticin 3147 was well tolerated within the udder and elicited only a temporary increase in somatic cell count to 5.7 x 10(5)/ml (88 h after infusion) in a previously uninfected lactating udder quarter. Therefore, we concluded that this nonantibiotic approach to mastitis prevention may contribute to a reduction in the routine application of antibiotics at drying off in the future.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10629810     DOI: 10.3168/jds.S0022-0302(99)75519-0

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  14 in total

1.  Generation of food-grade lactococcal starters which produce the lantibiotics lacticin 3147 and lacticin 481.

Authors:  Lisa O'Sullivan; Maire P Ryan; R Paul Ross; Colin Hill
Journal:  Appl Environ Microbiol       Date:  2003-06       Impact factor: 4.792

2.  Strong synergy between a eukaryotic antimicrobial peptide and bacteriocins from lactic acid bacteria.

Authors:  Torben Lüders; Gunn Alice Birkemo; Gunnar Fimland; Jon Nissen-Meyer; Ingolf F Nes
Journal:  Appl Environ Microbiol       Date:  2003-03       Impact factor: 4.792

3.  In Vitro Characterization of Lactic Acid Bacteria Isolated from Bovine Milk as Potential Probiotic Strains to Prevent Bovine Mastitis.

Authors:  Matías S Pellegrino; Ignacio D Frola; Berardo Natanael; Dino Gobelli; María E F Nader-Macias; Cristina I Bogni
Journal:  Probiotics Antimicrob Proteins       Date:  2019-03       Impact factor: 4.609

4.  Update on the development of a novel dry cow therapy using a bismuth-based intramammary teat seal in combination with the bacteriocin lacticin 3147.

Authors:  Fiona Crispie; James Flynn; R Paul Ross; Colin Hill; William J Meaney
Journal:  Ir Vet J       Date:  2004-11-01       Impact factor: 2.146

Review 5.  Targeting gut microbiota as a possible therapy for mastitis.

Authors:  Xiaoyu Hu; Shumin Li; Yunhe Fu; Naisheng Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-05-11       Impact factor: 3.267

6.  Otitis Media: A Review, with a Focus on Alternative Treatments.

Authors:  L M T Dicks; H Knoetze; C A van Reenen
Journal:  Probiotics Antimicrob Proteins       Date:  2009-03-04       Impact factor: 5.265

7.  Dry cow therapy with a non-antibiotic intramammary teat seal - a review.

Authors:  Fiona Crispie; James Flynn; R Paul Ross; Colin Hill; William J Meaney
Journal:  Ir Vet J       Date:  2004-07-01       Impact factor: 2.146

8.  Relatedness between the two-component lantibiotics lacticin 3147 and staphylococcin C55 based on structure, genetics and biological activity.

Authors:  Eileen B O'Connor; Paul D Cotter; Paula O'Connor; Orla O'Sullivan; John R Tagg; R Paul Ross; Colin Hill
Journal:  BMC Microbiol       Date:  2007-04-02       Impact factor: 3.605

9.  A mouse mastitis model to study the effects of the intramammary infusion of a food-grade Lactococcus lactis strain.

Authors:  Cristina Camperio; Federica Armas; Elena Biasibetti; Paolo Frassanito; Carlo Giovannelli; Liliana Spuria; Claudia D'Agostino; Sabrina Tait; Maria Teresa Capucchio; Cinzia Marianelli
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

10.  A Live Bio-Therapeutic for Mastitis, Containing Lactococcus lactis DPC3147 With Comparable Efficacy to Antibiotic Treatment.

Authors:  Michael Kitching; Harsh Mathur; James Flynn; Noel Byrne; Pat Dillon; Riona Sayers; Mary C Rea; Colin Hill; R Paul Ross
Journal:  Front Microbiol       Date:  2019-09-27       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.